2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: Statement of endorsement by the NVVC

Fabrice M.A.C. Martens; Frank L.J. Visseren; Jan Westerink; Ruud F. Spee; El Messaoudi Saloua; Arend Mosterd; Louis M. Handoko; Maarten J.G. Leening; Tjeerd J. Römer; Andries Slootweg; Arianne C. van Bon; Martin E.W. Hemels

doi:10.1007/s12471-025-01967-y

2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: Statement of endorsement by the NVVC

Fabrice M.A.C. Martens^*
, Frank L.J. Visseren
, Jan Westerink
, Ruud F. Spee
, El Messaoudi Saloua
, Arend Mosterd
, Louis M. Handoko
, Maarten J.G. Leening
, Tjeerd J. Römer
, Andries Slootweg
, Arianne C. van Bon
, Martin E.W. Hemels

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

37 Downloads (Pure)

Abstract

The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and provide recommendations on CVD risk stratification, as well as on screening. This article provides a summary of the key recommendations and a practical approach for cardiologists in the Netherlands to implement these guidelines in daily clinical practice by focusing on recommendations related to type 2 diabetes, including a step-by-step scheme for prescription of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2) inhibitors and Glucagon-like peptide‑1 (GLP-1) receptor agonists. These agents can be prescribed in addition to standard care, and independent of glucose control, target HbA1c, or obesity.

Original language	English
Pages (from-to)	216-225
Number of pages	10
Journal	Netherlands Heart Journal
Volume	33
Issue number	7
DOIs	https://doi.org/10.1007/s12471-025-01967-y
Publication status	Published - Jul 2025

Keywords

Cardiovascular disease
Diabetes
GLP‑1 receptor agonists
SGLT2 inhibitors

Access to Document

10.1007/s12471-025-01967-yLicence: CC BY

2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetesFinal published version, 4.31 MBLicence: CC BY

Cite this

Martens, F. M. A. C., Visseren, F. L. J., Westerink, J., Spee, R. F., Saloua, E. M., Mosterd, A., Handoko, L. M., Leening, M. J. G., Römer, T. J., Slootweg, A., van Bon, A. C., & Hemels, M. E. W. (2025). 2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: Statement of endorsement by the NVVC. Netherlands Heart Journal, 33(7), 216-225. https://doi.org/10.1007/s12471-025-01967-y

@article{a39064b8970340a6ab78e682f0bb4b2c,

title = "2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: Statement of endorsement by the NVVC",

abstract = "The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and provide recommendations on CVD risk stratification, as well as on screening. This article provides a summary of the key recommendations and a practical approach for cardiologists in the Netherlands to implement these guidelines in daily clinical practice by focusing on recommendations related to type 2 diabetes, including a step-by-step scheme for prescription of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2) inhibitors and Glucagon-like peptide‑1 (GLP-1) receptor agonists. These agents can be prescribed in addition to standard care, and independent of glucose control, target HbA1c, or obesity.",

keywords = "Cardiovascular disease, Diabetes, GLP‑1 receptor agonists, SGLT2 inhibitors",

author = "Martens, \{Fabrice M.A.C.\} and Visseren, \{Frank L.J.\} and Jan Westerink and Spee, \{Ruud F.\} and Saloua, \{El Messaoudi\} and Arend Mosterd and Handoko, \{Louis M.\} and Leening, \{Maarten J.G.\} and R{\"o}mer, \{Tjeerd J.\} and Andries Slootweg and \{van Bon\}, \{Arianne C.\} and Hemels, \{Martin E.W.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = jul,

doi = "10.1007/s12471-025-01967-y",

language = "English",

volume = "33",

pages = "216--225",

journal = "Netherlands Heart Journal",

issn = "1568-5888",

publisher = "Bohn Stafleu van Loghum",

number = "7",

}

Martens, FMAC, Visseren, FLJ, Westerink, J, Spee, RF, Saloua, EM, Mosterd, A, Handoko, LM, Leening, MJG, Römer, TJ, Slootweg, A, van Bon, AC & Hemels, MEW 2025, '2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: Statement of endorsement by the NVVC', Netherlands Heart Journal, vol. 33, no. 7, pp. 216-225. https://doi.org/10.1007/s12471-025-01967-y

2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: Statement of endorsement by the NVVC. / Martens, Fabrice M.A.C.; Visseren, Frank L.J.; Westerink, Jan et al.
In: Netherlands Heart Journal, Vol. 33, No. 7, 07.2025, p. 216-225.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - 2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes

T2 - Statement of endorsement by the NVVC

AU - Martens, Fabrice M.A.C.

AU - Visseren, Frank L.J.

AU - Westerink, Jan

AU - Spee, Ruud F.

AU - Saloua, El Messaoudi

AU - Mosterd, Arend

AU - Handoko, Louis M.

AU - Leening, Maarten J.G.

AU - Römer, Tjeerd J.

AU - Slootweg, Andries

AU - van Bon, Arianne C.

AU - Hemels, Martin E.W.

PY - 2025/7

Y1 - 2025/7

N2 - The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and provide recommendations on CVD risk stratification, as well as on screening. This article provides a summary of the key recommendations and a practical approach for cardiologists in the Netherlands to implement these guidelines in daily clinical practice by focusing on recommendations related to type 2 diabetes, including a step-by-step scheme for prescription of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2) inhibitors and Glucagon-like peptide‑1 (GLP-1) receptor agonists. These agents can be prescribed in addition to standard care, and independent of glucose control, target HbA1c, or obesity.

AB - The 2023 update of the European Society of Cardiology guidelines for the management of cardiovascular disease (CVD) in patients with diabetes are designed to guide prevention, early diagnosis, and management of CVD in patients with diabetes and provide recommendations on CVD risk stratification, as well as on screening. This article provides a summary of the key recommendations and a practical approach for cardiologists in the Netherlands to implement these guidelines in daily clinical practice by focusing on recommendations related to type 2 diabetes, including a step-by-step scheme for prescription of Sodium-Glucose Transport Protein 2 Inhibitors (SGLT2) inhibitors and Glucagon-like peptide‑1 (GLP-1) receptor agonists. These agents can be prescribed in addition to standard care, and independent of glucose control, target HbA1c, or obesity.

KW - Cardiovascular disease

KW - Diabetes

KW - GLP‑1 receptor agonists

KW - SGLT2 inhibitors

UR - https://www.scopus.com/pages/publications/105010529259

U2 - 10.1007/s12471-025-01967-y

DO - 10.1007/s12471-025-01967-y

M3 - Article

C2 - 40634662

AN - SCOPUS:105010529259

SN - 1568-5888

VL - 33

SP - 216

EP - 225

JO - Netherlands Heart Journal

JF - Netherlands Heart Journal

IS - 7

ER -

2023 European Society of Cardiology guidelines for the management of cardiovascular disease in patients with diabetes: Statement of endorsement by the NVVC

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this